ImnovidĀ® approved for myeloma patients in Wales

The All Wales Medicines Strategy Group (AWMSG) has approved the use of ImnovidĀ® (pomalidomide) for relapsed and/or refractory myeloma patients who have previously received both bortezomib and lenalidomide. The approval was based on trial data demonstrating that Imnovid, in combination with dexamethasone, significantly improved progression-free and overall survival compared to dexamethasone alone. Imnovid is also…

Details